GC-MS identification of sympathomimetic amine drugs in urine: Rapid methodology applicable for emergency clinical toxicology

Journal of Analytical Toxicology

Volumn 24, Issue 3, 2000, Pages 211-222

  Valentine, Jimmie L ^a   Middleton, Rosalyn ^a  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEPRAMONE; AMPHETAMINE; BENZPHETAMINE; CATHINONE; EPHEDRINE; FENFLURAMINE; MAZINDOL; MESCALINE; METHAMPHETAMINE; METHCATHINONE; METHYLPHENIDATE; PEMOLINE; PHENDIMETRAZINE; PHENTERMINE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; SELEGILINE; TRANYLCYPROMINE;

ARTICLE; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; GAS CHROMATOGRAPHY; MASS SPECTROMETRY;

EID: 0034063415     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/24.3.211     Document Type: Article

References (104)

1. T.B. Vree, A.T. Muskens, and J.M. van Rossum. Some physicochemical properties of amphetamine and related drugs. J. Pharm. Pharmacol. 21: 774-775 (1969).
2. S.J. Mule and G.A. Casella. Confirmation of marijuana, cocaine, morphine, codeine, amphetamine, methamphetamine, phencyclidine by GC/MS in urine following immunoassay screening. J. Anal. Toxicol. 12: 102-107 (1988).
3. C.L. Hornbeck and R.J. Czarny. Quantitation of methamphetamine and amphetamine in urine by capillary GC/MS. Part I. Advantages of tried loroacetylderivatization. J. Anal. Toxicol. 13: 144-149 (1989).
4. R.J. Czarny and C.L. Hornbeck. Quantitation of methamphetamine and amphetamine in urine by capillary GC/MS. Part II. Derivatization with 4-carbethoxyhexafluorobutyryl chloride. J. Anal. Toxicol. 13: 257-262 (1989).
5. B.K. Gan, D. Baugh, R.H. Liu, and A.S. Walia. Simultaneous analysis of amphetamine, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) in urine samples by solid-phase extraction, derivatization, and gas chromatography/mass spectrometry. J. Forensic Sci. 36: 1331-1341 (1991).
6. R.O. Hughes, W.E. Bronner, and M.L. Smith. Detection of amphetamine and methamphetamine in urine by gas chromatography/mass spectrometry following derivatization with (-)-menthyl chloroformate. J. Anal. Toxicol. 15: 256-259 (1991).
7. P. Ellerbe, T. Long, and M.J. Welch. The determination of amphetamine and methamphetamine in a lyophilized human urine reference material. J. Anal. Toxicol. 17: 165-170 (1993).
8. D.E. Blandford and P.R. Desjardins. Detection and identification of amphetamine and methamphetamine in urine by GC/MS. Clin. Chem. 40: 145-147 (1994).
9. R. Meatherall. Rapid GC-MS confirmation of urinary amphetamine and methamphetamine as their propylchloroformate derivatives. J. Anal. Toxicol. 19: 316-322 (1995).
10. P. Dallakian, H. Bedzikiewicz, and H. Brzezinka. Detection and quantitation of amphetamine and methamphetamine: Electron impact and chemical ionization with ammonia-comparative investigation on Shimadzu QP 5000 GC-MS system. J. Anal. Toxicol. 20: 255-261 (1996).
11. M.R. Lee, S.C. Yu, C.L. Lin, Y.C. Yeh, Y.L. Chen, and S.H. Hu. Solid-phase extraction in amphetamine and methamphetamine analysis of urine. J. Anal. Toxicol. 21: 278-282 (1997).
12. A. Dasgupta and J. Spies. A rapid novel derivatization of amphetamine and methamphetamine using 2,2,2-trichloroethyl chloroformate for gas chromatography electron ionization and chemical ionization mass spectrometric analysis. Am. J. Clin. Pathol. 109: 527-532 (1998).
13. A.S. Christophersen, A. Bugge, E. Dahlin, J. Morland, and G. Wethe. Interference with analysis of amphetamine in blood by N-ethylbenzenamine from rubber septums. J. Anal. Toxicol. 12: 147-149 (1988).
14. G.A. Eiceman, C.S. Leasure, and S.L. Selim. Quantitative investigation of rapid injector port derivatization of amphetamine using trifluoroacetic anhydride with packed and capillary column GC and GC/MS methods. J. Chromatogr. Sci. 22: 509-513 (1984).
15. S. Suzuki, T. Inoue, H. Hori, and S. Inayama. Analysis of methamphetamine in hair, nail, sweat, and saliva by mass fragmentography. J. Anal. Toxicol. 13: 176-178 (1989).
16. O. Suzuki, H. Hattori, and M. Asano. Nails as useful material for detection of methamphetamine or amphetamine abuse. Forensic Sci. Int. 24: 9-16 (1984).
17. I. Ishiyama, T. Nagai, and S. Toshida. Detection of basic drugs (methamphetamine, antidepressants, and nicotine) from human hair. J. Forensic Sci. 28: 380-385 (1983).
18. O. Suzuki, H. Hattori, and M. Asano. Detection of methamphetamine and amphetamine in a single human hair by gas chromatography/chemical ionization mass spectrometry. J. Forensic Sci. 29: 611-617 (1984).
19. Y. Makahara, K. Takahashi, M. Shimamine, and Y. Takeda. Hair analysis for drug abuse: I. Determination of methamphetamine and amphetamine in hair by stable isotope dilution gas chromatography/mass spectrometry method. J. Forensic Sci. 36: 70-78 (1991).
20. T. Kojima, I. Une, and M. Yashiki. Cl-mass fragmentographic analysis of methamphetamine and amphetamine in human autopsy tissues after acute methamphetamine poisoning. Forensic Sci. Int. 21: 253-258 (1983).
21. J.E. Meeker and P.C. Reynolds. Postmortem tissue methamphetamine concentrations following selegiline administration. J. Anal. Toxicol. 14: 330-331 (1990).
22. T. Kraemer and H.H. Maurer. Determination of amphetamine, methamphetamine, and amphelamine-derived designer drugs or medicaments in blood and urine. J. Chromatogr. B 713: 163-187 (1998).
23. Department of Health and Human Services. Mandatory guidelines for Federal workplace drug testing programs; final guidelines; notice. Fed. Regist. 53: 11979 (1988).
24. Department of Health and Human Services. Procedures for transportation workplace drug and alcohol testing prgrams; final rule. Fed. Regist. 49: 42998 (1994).
25. E.M. Thurman, M.J. Pederson, R.L. Stout, and T. Martin. Distinguishing sympathomimetic amines from amphetamine and methamphetamine in urine by gas chromatography/mass spectrometry. J. Anal. Toxicol. 16: 19-27 (1992).
26. C.L. Hornbeck, J.E. Carrig, and R.J. Czarny. Detection of a GC/MS artifact peak as methamphetamine. J. Anal. Toxicol. 17: 257-263 (1993).
27. M.A. ElSohly, D.F. Stanford, D. Sherman, H. Shah, D. Bernot, and C.E. Turner. A procedure for eliminating interferences from ephedrine and related compounds in the GC/MS analysis of amphetamine and methamphetamine. J. Anal. Toxicol. 16: 109-111 (1992).
28. B.D. Paul, M.R. Past, R.M. McKinley, J.D. Foreman, L.K. McWhorter, and J.J. Snyder. Amphetamine as an artifact of methamphetamine during periodate degradation of interfering ephedrine, pseudoephedrine, and phenylpropanolamine: an improved procedure for accurate quantitation of amphetamines in urine. J. Anal. Toxicol. 18: 331-336 (1994).
29. L. Smith. Collapse with death following the use of amphetamine sulfate. J. Am. Med. Assoc. 113: 1022-1023 (1939).
30. K.E. Von Muhlendahl and E.G. Krienke. Fenfluramine poisoning. Clin. Toxicol. 14: 97-106 (1979).
31. B. Levine, Y.H. Caplan, and A.M. Dixon. A fatality involving phentermine. J. Forensic Sci. 29: 1242-1245 (1984).
32. P. Pentel. Toxicity of over-the-counter stimulants. J. Am. Med. Assoc. 252: 1898-1903 (1984).
33. R. Saken, G.L. Kates, and K. Miller. Drug-induced hypertension in infancy. J. Pediatr. 95: 1077-1079 (1979).
34. V. Borromeo-McGrail, J.M. Bordiuk, and M. Keitel. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. Pediatr. 51: 1032-1036 (1973).
35. J.L. Valentine and E.M. Komoroski. Use of a visual panel detection method for drugs of abuse: clinical and laboratory experience with children and adolescents. J. Pediatr. 126: 135-140 (1995).
36. L.P. James, H.C. Farrar, E.M. Komoroski, W.R. Wood, C.J. Graham, R.A. Bornemeier, and J.L. Valentine. Sympathomimetic drug use in adolescents presenting to a pediatric emergency department with chest pain. Clin. Toxicol. 36: 321-328 (1998).
37. M.D. Kogan, G. Pappas, S.M. Yu, and M. Kotelchuck. Over-thecounter medication use among U.S. preschool-age children. J. Am. Med. Assoc. 272: 1025-1030 (1994).
38. Package insert, EMIT II monoclonal amphetamine/methamphetamine assay. Syva Company, San Jose, CA.
39. W.C. Thompson and A. Dasgupta. Microwave-induced rapid preparation of fluoro derivatives of amphetamine, methamphetamine, and 3,4-methylenedioxymethamphetamine for GC-MS confirmation. Clin. Chem. 40: 1703-1706 (1994).
40. H. Tsuchihashi, K. Nakajima, M. Nishikawa, K. Shiomi, and S. Takahashi. Headspace gas chromatography of stimulants in urine by in-column trifluoroacetyl derivatization method. J. Chromatogr. 467: 227-235 (1989).
41. L.G. Dring, R.L Smith, and R.T. Williams. The metabolic fate of amphetamine in man and other species. Biochem. J. 116: 425-435 (1970).
42. 17-amphetamine in urine in man. Biochem. J. 129: 23-24 (1972).
43. A.H. Beckett, R.T. Courts, and F.A. Ogunbona. Metabolism of amphetamines. Identification of N-oxygenated products by gas chromatography and mass spectrometry. J. Pharm. Pharmacol. 25: 708-717 (1973).
44. A.K. Cho and J. Wright. Pathways of metabolism of amphetamine and related compounds. Life Sci. 22: 363-372 (1978).
45. J.T. Cody. Determination of methamphetamine enantiomer ratios in urine by gas chromatography-mass spectrometry. J. Chromatogr. 580: 77-95 (1992).
46. J.T. Cody and S. Valtier. Detection of amphetamine and methamphetamine following administration of benzphetamine. J. Anal. Toxicol. 22: 299-309 (1998).
47. J. Marsel, G. Doring, G. Remberg, and G. Spiteller. Methamphetamine - a metabolite of the anorectics benzphetamine and furfenorex. Z. Rechtsmed. 70: 245-250 (1972).
48. K. Mathys and R. Brenneisen. Determination of (S)-(-)-cathinone and its metabolites (R,S)-(-)-norephedrine and (R,R)-(-)-norpseudoephedrine in urine by high-performance liquid chromatography with photodiode-array detection. J. Chromatogr. 593: 79-85 (1992).
49. A.N. Guantai and C.K. Maita. Metabolism of cathinone to d-norpseudoephedrine in humans. J. Pharm. Sci. 72: 1217-1218 (1983).
50. 14 hydrochloride by the human. J. Pharmacol. Exptl. Ther. 159: 372-378 (1968).
51. F. Banci, G.P. Cartoni, A. Cavalli, and A. Monai. Excretion of some basic metabolites of diethylpropion in man and rabbit. Arzneimittelforschung 21: 1616-1618 (1971).
52. B. Testa and A.H. Beckett. The metabolism of diethylpropion in man; influence of changes in drug formulation and urinary pH. Pharm. Acta Helv. 49: 21-27 (1974).
53. D. Mihailova, A. Rosen, B. Testa, and A.H. Beckett. A pharmacokinetic investigation of the distribution and elimination of diethylpropion and its metabolites in man. J. Pharm. Pharmacol. 26: 711-721 (1974).
54. A.H. Beckett and M. Stanojcic. Re-evaluation of the metabolism and excretion of diethylpropion in non-sustained and sustained release formulations. J. Pharm. Pharmacol. 39: 409-415 (1987).
55. G.R. Wilkinson and A.H. Beckett. Absorption, metabolism, and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. J. Pharmacol. Exp. Ther. 162: 139-147 (1968).
56. G.R. Wilkinson and A.H. Beckett. Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. J. Pharm. Sci. 57: 1933-1938 (1968).
57. P.S. Sever, L.G. Dring, and R.T. Williams. The metabolism of (-)-ephedrine in man. Eur. J. Pharmacol. 9: 193-198 (1975).
58. S. Baba, Y. Kuroda, and M. Horie. Studies on drug metabolism by use of isotopes. XXVIII. Biological isotope effect for deuterated ephedrine. Biomed. Environ. Mass Spectrom. 13: 137-140 (1986).
59. A.H. Beckett and L.G. Brookes. The absorption and urinary excretion in man of fenfluramine and its main metabolite. J. Pharm. Pharmacol. 19Suppl: 42S-49S (1967).
60. R.B. Bruce and W.R. Maynard, Jr. Fenfluramine metabolism. J. Pharm. Sci. 57: 1173-1176 (1968).
61. S. Caccia, M. Ballabio, and P. De Ponte. Pharmacokinetics of fenfluramine enantiomers in man. Eur. J. Drug Metab. Pharmacokinet. 4: 129-132 (1979).
62. K.K. Midha, E.M. Hawes, J.K. Cooper, J.W. Hubbard, K. Bailey, and I.J. McGilveray. The identification of two new urinary metabolites of fenfluramine in man. Xenobiotica 13: 31-38 (1983).
63. R. Brownsill, D. Wallace, A. Taylor, and B. Campbell. Study of human urinary metabolism of fenfluramine using gas chromatography-mass spectrometry. J. Chromatogr. 562: 267-277 (1991).
64. 14C-(±)-fenfluramine in mouse, rat, dog and man. Xenobiotica 22: 1251-1266 (1992).
65. A.S. Gross, A.C. Phillips, J. Boutagy, and G.M. Shenfield. Determination of dexfenfluramine and nordexfenfluramine in urine by high-performance liquid chromatography using ultra violet detection. J. Chromatogr. 621: 115-120 (1993).
66. H.A. Dugger, V.O. Madrid, K.C. Talbot, R.A. Coombs, and B.A. Orwig. Biotransformation of mazindol. III. Comparison of metabolism in rat, dog, and man. Drug Metab. Dispos. 7: 132-137 (1979).
67. H.H. Maurer. On the metabolism and the lexicological analysis of methylenedioxyphenyl-alkylamine designer drugs by gas chromatography-mass spectrometry. Ther. Drug Monit. 18: 465-470 (1996).
68. H.K. Ensslin, K.A. Kovar, and H.H. Maurer. Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, Eve) and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B 683: 189-197 (1966).
69. H.K. Ensslin, H.H. Maurer, E. Gouzoulis, L. Hermle, and K.A. Kovar. Metabolism of racemic 3,4-rnethylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab. Dispos. 24: 813-820 (1996).
70. W. Pisternick, K.A. Kovar, and H. Ensslin. High-performance thin-layer Chromatographic determination of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in urine and comparison with high-performance liquid chromatography. J. Chromatogr. B 688: 63-69 (1997).
71. G.W. Kunsman, B. Levine, J.J. Kuhlman, R.L. Jones, R.O. Hughes, C.I. Fujiyama, and M.L. Smith. MDA-MDMA concentrations in urine specimens. J. Anal. Toxicol. 20: 517-521 (1996).
72. H.J. Helmlin, K. Bracher, D. Bourquin, D. Vonlanther, and R. Brenneisen. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J. Anal. Toxicol. 20: 432-440 (1996).
73. M. Lanz, R. Brenneisen, and W. Thormann. Enantioselective determination of 3,4-methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. Electrophoresis 18: 1035-1043 (1997).
74. D. de Boer, L.P. Tan, P. Gorter, R.M. van de Wal, J.J. Kettenes van den Bosch, E.A. de Bruijn, and R.A. Maes. Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry. J. Mass Spectrom. 32: 1236-1246 (1997).
75. K.D. Charalampous, K.E. Walker, and J. Kinross-Wright. Metabolic fate of mescaline in man. Psychopharmacol. 9: 48-63 (1966).
76. L. Demisch, P. Kaczmarczyk, and N. Seiler. 3,4,5-Trimethoxybenzoic acid, a new mescaline-metabolite in humans. Drug Metab. Dispos. 6: 507-509 (1978).
77. A.H. Beckett and M. Rowland. Urinary excretion of methylamphetamine in man. Nature 206: 1260-1 (1965).
78. T.B. Vree, A.T. Muskens, and J.M. van Rossum. Deuterium isotope effects and stereochemistry in the dealkylation and deamination of amphetamines and ephedrines in man. Xenobiotica 1: 385-386 (1971).
79. T.B. Vree, J.P. Corgels, A.T. Muskens, and J.M. van Rossum. Deuterium isotope effects in the metabolism of N-alkylsubstituted amphetamines in man. Clin. Chim. Acta 34: 333-344 (1971).
80. K. Shimosato, H. Oda, M. Ohmae, M. Tomita, and Y. Doi. Biphasic effects of alcohol drinking on methamphetamine metabolism in man. Alcohol Alcoholism 23: 351-357 (1988).
81. K. Shimosato. Urinary excretion of p-hydroxylated methamphetamine metabolites in man. II. Effect of alcohol intake on methamphetamine metabolism. Pharmacol. Biochem. Behav. 29: 733-740 (1988).
82. G.L. Henderson, M.R. Harkey, and Y.T. Chueh. Metabolism of 4-methylaminorex ("EU4EA") in the rat. J. Anal. Toxicol. 19: 563-570 (1995).
83. 14C: studies in man and animals. J. Pharmacol. Exp. Ther. 191: 535-547 (1974).
84. E. Redalieu, M.F. Bartlett, L.M. Waldes, W.R. Darrow, H. Egger, and W.E. Wagner. A study of methylphenidate in man with respect to its major metabolite. Drug Metab. Dispos. 10: 708-709 (1982).
85. T. Aoyama, H. Kotaki, Y. Honda, and F. Nakagawa. Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J. Pharm. Sci. 79: 465-469 (1990).
86. N.R. Srinivas, J.W. Hubbard, E.D. Korchinski, and K.K. Midha. Stereoselective urinary pharmacokinetics of dl-theromethylphenidate and its major metabolite in humans. J. Pharm. Sci. 81: 747-749 (1992).
87. S.Y. Chu and S.T. Sennello. Gas chromatographic determination of pemoline in biological fluids using electron capture detection. J. Chromatogr. 137: 343-350 (1977).
88. A.H. Beckett and M.A. Salami. A note on the identification of N-hydroxyphenmetrazine as a metabolic product of phendimetrazine and phenmetrazine. J. Pharm. Pharmacol. 24: 900-902 (1972).
89. 3H-phenylephrine in man. Eur. J. Clin. Pharmacol. 21: 335-341 (1982).
90. J.R. Crowley, C.M. Williams, and M.J. Fregly. In-vivo catechol amine formation from phenylephrine. J. Pharm. Pharmacol. 35: 264-265 (1983).
91. A.H. Beckett and L.G. Brookes. The metabolism and urinary excretion in man of phentermine, and the influence of N-methyl and p-chloro-substitution. J. Pharm. Pharmacol. 23: 288-284 (1971).
92. A.K. Cho. The identification of p-hydroxyphentermine as a urinary metabolite of phentermine. Res. Commun. Chem. Pathol. Pharmacol. 7: 67-78 (1974).
93. A.M. Beckett and P.M. Belanger. Metabolism of chlorphentermine and phentermine in man to yield hydroxylamino, C-nitroso-and nitro-compounds. J. Pharm. Pharmacol. 26: 205-206 (1974).
94. D.C. Brater, S. Kaojarern, L.Z. Benet, E.T. Lin, T. Lockwood, R.C. Morris, E.J. McSherry, and K.L. Melmon, Renal excretion of pseudoephedrine. Clin. Pharmacol. Ther. 28: 690-694 (1980).
95. S. Baba, Y. Kuroda, and M. Horie. Studies on drug metabolism by use of isotopes. XXIX. Studies of the differences in biological fates of ephedrine isomers by use of a pseudo-racemic mixture. Biomed. Environ. Mass Spectrom. 13: 141-143 (1986).
96. F.T. Delbeke and M. Debackere. The influence of diuretics on the excretion and metabolism of doping agents: Part IV. Pseudoephedrine. Biopharm. Drug Dispos. 12: 37-48 (1991).
97. G.P. Reynolds, J.D. Elsworth, K. Blau, M. Sandler, A.J. Lees, and G.M. Stern. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 6: 542-544 (1978).
98. F. Karoum, L.W. Chuang, T. Eisler, D.B. Calne, M.R. Liebowitz, F.M. Quitkin, D.F. Klein, and R.J. Wyatt. Metabolism of (-)-deprenyl to amphetamine and methamphetamine may be responsible for deprenyls therapeutic benefit: a biochemical assessment. Neurology 32: 503-509 (1982).
99. E.H. Heinonen, V. Myllyla, K. Sotaniemi, R. Lamintausta, J.S. Salonen, M. Anttila, M. Savijarvi, M. Kotila, and U.K. Rinne. Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. Suppl. 126: 93-99 (1989).
100. H.H. Maurer and T. Kraemer. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch. Toxicol. 66: 675-678 (1992).
101. H.S. Shin. Metabolism of selegiline in humans. Identification, excretion, and sterochemistry of urine metabolites. Drug Metab. Dispos. 25: 657-662 (1997).
102. J. Lengyel, K. Magyar, I. Hollosi, T. Bartok, M. Bathori, H. Kalasz, and S. Furst. Urinary excretion of deprenyl metabolites. J. Chromatogr. A 762: 321-326 (1997).
103. J.L. Valentine, G.L. Kearns, C. Sparks, L.G. Letzig, C.R. Valentine, S.A. Shappell, D.F. Neri, and C.A. DeJohn. GC-MS determination of amphetamine and methamphetamine in human urine for 12 hours following oral administration of dextro-methamphetamine: lack of evidence supporting the established forensic guidelines for methamphetamine confirmation. J. Anal. Toxicol. 19: 581-590 (1995).
104. J.H. Autry, III. Notice to all DHHS/NIDA certified laboratories. Division of Applied Research, NIDA, Washington, D.C., February 4, 1991.